Wall Street can be cruel that way.
Surfaxin is a humanized surfactant so, therefore, better than existing competitors, which are all animal-based. That should help Surfaxin gain market share but the total U.S. market is only $75 million, probably a bit more in Europe. It's a niche drug in a niche indication, which also helps explain why Discovery's stock price hasn't taken off following approval.
-- Written by Adam Feuerstein in Boston
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.>To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.